Home

Phio Pharmaceuticals Corp. - Common Stock (PHIO)

2.0400
-0.1900 (-8.52%)
NASDAQ · Last Trade: Apr 27th, 5:08 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close2.230
Open2.210
Bid2.060
Ask2.100
Day's Range1.970 - 2.300
52 Week Range0.9657 - 9.790
Volume444,978
Market Cap9.75M
PE Ratio (TTM)-0.3148
EPS (TTM)-6.5
Dividend & YieldN/A (N/A)
1 Month Average Volume8,347,567

Chart

About Phio Pharmaceuticals Corp. - Common Stock (PHIO)

Phio Pharmaceuticals Corp is a biotechnology company focused on the development of innovative therapies for cancer treatment. The company specializes in leveraging its proprietary delivery platform to enhance the effectiveness of immune-based therapies, particularly in the area of adoptive cell therapy. By utilizing their unique technology, Phio aims to create treatments that can empower the body’s immune system to better target and destroy cancer cells, ultimately improving patient outcomes and offering new hope in the fight against various types of cancer. Read More

News & Press Releases

Top movers in Wednesday's sessionchartmill.com
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · April 23, 2025
Top movers analysis in the middle of the day on 2025-04-23: top gainers and losers in today's session.chartmill.com
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.
Via Chartmill · April 23, 2025
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · April 23, 2025
The market is filled with gapping stocks in Wednesday's session.chartmill.com
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via Chartmill · April 23, 2025
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · April 16, 2025
Tuesday's after hours session: top gainers and loserschartmill.com
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
Via Chartmill · April 15, 2025
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · April 15, 2025
The trading volume of these stocks is deviating from the norm in today's session.chartmill.com
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Via Chartmill · April 10, 2025
Which stocks are moving on Wednesday?chartmill.com
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · April 9, 2025
Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilledstocktwits.com
CEO Robert Bitterman said the company is optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer.
Via Stocktwits · April 9, 2025
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · April 9, 2025
The market is filled with gapping stocks in Wednesday's session.chartmill.com
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Via Chartmill · April 9, 2025
Crude Oil Down 4%; Neogen Shares Plunge After Q3 Resultsbenzinga.com
Via Benzinga · April 9, 2025
Top movers in Wednesday's pre-market sessionchartmill.com
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Via Chartmill · April 9, 2025
Nasdaq Gains Over 100 Points; Delta Air Lines Posts Upbeat Earningsbenzinga.com
Via Benzinga · April 9, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · April 9, 2025
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
Marlborough, Massachusetts--(Newsfile Corp. - April 9, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing...
Via Newsfile · April 9, 2025
Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894
To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3,...
Via Newsfile · April 3, 2025
Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update
Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-7623rd Cohort now fully enrolled in on-going clinical studyMarlborough, Massachusetts--(Newsfile...
Via Newsfile · March 31, 2025
American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
Marlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Via Newsfile · March 10, 2025
Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
Marlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Via Newsfile · March 5, 2025
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Marlborough, Massachusetts--(Newsfile Corp. - February 26, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) a clinical-stage biotechnology company developing therapeutics that...
Via Newsfile · February 26, 2025
Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors
Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Via Newsfile · February 20, 2025
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Marlborough, Massachusetts--(Newsfile Corp. - February 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Via Newsfile · February 3, 2025
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Marlborough, Massachusetts--(Newsfile Corp. - January 22, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Via Newsfile · January 22, 2025